About

At Cellectar we believe that our targeted delivery platform has the potential to develop new and better treatments for patients and to prolong and improve their quality of life.

Our Company

We foster a culture of innovation, collaboration, and determination that begins with our leaders and permeates throughout the entire company. It drives all our efforts and fuels our passion to make a significant and positive impact in the lives of patients, families and caregivers.

Targeted Delivery Platform

Our next generation technology possesses the potential to deliver a wide variety of molecules to cancer cells and generate better patient outcomes including greater efficacy and fewer side effects.

Platform

Product Pipeline

Iopofosine is a Phospholipid Drug Conjugate™ (PDC) that uses our PLE Platform that provides targeted delivery of the radioisotope iodine-131 to a large number different tumor types. Our pipeline also consists of other PDC programs - Each have different therapeutic molecules aimed at combating a variety of cancers.

Pipeline

Clinical Studies

Our lead program, iopofosine is currently being evaluated in a Phase 2 study for Waldenstrom’s macroglobulinemia. In addition, iopofosine is also being evaluated in multiple Phase 1 and Phase 2 clinical studies including other B-cell malignancies like multiple myeloma and several pediatric solid tumors, such as various brain tumors and soft tissue sarcomas.

Clinical Studies

Our Strategy

Calculated Outsourcing Fuels Drug Discovery and Development

At Cellectar, we recognize that sometimes the best and most effective way to produce both new and improved treatment options for cancer patients is through collaboration and execution of strategic business alliances. Doing so facilitates a path for efficiently and cost-effectively designing, researching, and advancing product candidates.

Iterative Screening Paradigm

Our unique approach allows us to rapidly and systematically screen multiple series’ of PDCs to produce optimal product candidates.

Strategic Drug Development

We are advancing an expanding pipeline of product candidates for diseases possessing clear unmet need. Our development efforts focus on product candidates with the potential for accelerated regulatory approval and commercialization. In addition to providing treatment options in areas of high unmet medical need, the company benefits from operating in highly scalable markets with limited competition, which reduces required commercial and medical investments and inherent risk.

Collaboration Engagement is Critical to Future Innovation and Growth

We assess identified and proposed collaboration(s) that will supplement internal resources, help us gain access to novel molecules for our PLEs, accelerate product candidate development and broaden our product pipeline. We expect some of these collaborations generate near-term capital and result in opportunities for Cellectar to further expand its portfolio.

Partnerships

Our executive team boasts extensive healthcare leadership experience within notable companies such as Novartis, Bristol Myers Squibb, Melinta Therapeutics, Abbott and more.

Management Team Board of Directors